Literature DB >> 23959995

Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.

Van T Hoang1, Isabel Hoffmann, Karina Borowski, Abraham Zepeda-Moreno, Dan Ran, Eike C Buss, Patrick Wuchter, Volker Eckstein, Anthony D Ho.   

Abstract

Mounting evidences indicate that leukemic cells in patients with acute myeloid leukemia (AML) are derived from leukemia stem cells (LSC). In analogy to normal hematopoietic stem cells (HSC), LSC remain mostly dormant and are hence resistant to conventional chemotherapy. Residual, physiological HSC exist alongside with LSC, with heterogeneous dominance of LSC over HSC in individual patients. We have devised a flow cytometric method for the identification and separation of these two stem cell populations based on surface antigen markers such as CD34, CD38, lineage aberrant markers, and aldehyde dehydrogenase (ALDH) enzyme activity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23959995     DOI： 10.1007/978-1-62703-508-8_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  7 in total

1.  N,N-diethylaminobenzaldehyde targets aldehyde dehydrogenase to eradicate human pancreatic cancer cells.

Authors:  Wenwen Wang; Shiya Zheng; Haiju He; Hao Ge; Borhan R Saeed
Journal:  Exp Ther Med       Date:  2020-04-27       Impact factor: 2.447

2.  MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.

Authors:  Chen Tian; M James You; Yong Yu; Lei Zhu; Guoguang Zheng; Yizhuo Zhang
Journal:  Tumour Biol       Date:  2015-12-17

3.  p65/RelA NF-κB fragments generated by RIPK3 activity regulate tumorigenicity, cell metabolism, and stemness characteristics.

Authors:  Yasmine Touil; Céline Latreche-Carton; Hassiba El Bouazzati; Anne-Lucie Nugues; Nathalie Jouy; Xavier Thuru; William Laine; Frederic Lepretre; Martin Figeac; Meryem Tardivel; Jérôme Kluza; Thierry Idziorek; Bruno Quesnel
Journal:  J Cell Biochem       Date:  2021-12-20       Impact factor: 4.480

4.  The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.

Authors:  Van T Hoang; Eike C Buss; Wenwen Wang; Isabel Hoffmann; Simon Raffel; Abraham Zepeda-Moreno; Natalia Baran; Patrick Wuchter; Volker Eckstein; Andreas Trumpp; Anna Jauch; Anthony D Ho; Christoph Lutz
Journal:  Int J Cancer       Date:  2015-01-14       Impact factor: 7.396

5.  Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.

Authors:  Maura Gasparetto; Shanshan Pei; Mohammad Minhajuddin; Nabilah Khan; Daniel A Pollyea; Jason R Myers; John M Ashton; Michael W Becker; Vasilis Vasiliou; Keith R Humphries; Craig T Jordan; Clayton A Smith
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

6.  The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.

Authors:  Charyguly Annageldiyev; Krishne Gowda; Trupti Patel; Priyanjali Bhattacharya; Su-Fern Tan; Soumya Iyer; Dhimant Desai; Sinisa Dovat; David J Feith; Thomas P Loughran; Shantu Amin; David Claxton; Arati Sharma
Journal:  Haematologica       Date:  2019-05-23       Impact factor: 9.941

7.  Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.

Authors:  G Venton; M Pérez-Alea; C Baier; G Fournet; G Quash; Y Labiad; G Martin; F Sanderson; P Poullin; P Suchon; L Farnault; C Nguyen; C Brunet; I Ceylan; R T Costello
Journal:  Blood Cancer J       Date:  2016-09-09       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.